Evolution of endoscopic mitral valve surgery in the era of transcatheter edge-to-edge repair:
an 11-year period at a high-volume center

 

Mitral regurgitation (MR) is the second most frequent valvular heart disease in Europe representing an important cause of morbidity and mortality. Despite increasing use of transcatheter edge-to-edge repair (TEER), endoscopic Mitral Valve Surgery (MVS) remains an established treatment approach aiming at reduced surgical trauma and improved recovery.

 

Between 2012 and 2022, a total of 1.037 consecutive patients underwent fully endoscopic MVS. Patients received limited right-sided anterolateral skin incision and 3D-camera visualization. Data was retrospectively analyzed.

 

Despite a continuous increase of patient age, prevalence of outcome-relevant comorbidities and surgical risk within the last decade, perioperative and longterm outcome of patients undergoing endoscopic MVS remain favorable. Particularly the possibility of concomitant cardiac procedures (e.g., tricuspid valve repair, ablation and LAA-occlusion) during endoscopic MVS, should be taken in consideration during routine heart-team discussion to determine the appropriate treatment option.